ReviewJournal of mid-life health
Dry Eye Syndrome in Menopause and Perimenopausal Age Group.
Review in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- The Association Between Genetic Polymorphisms in Estrogen Receptor Genes and the Risk of Ocular Disease: A Meta-AnalysisTurkish journal of ophthalmology · 2020Pooled it
- Sex hormone therapy's effect on dry eye syndrome in postmenopausal women: A meta-analysis of randomized controlled trials.Medicine · 2018Pooled it
- Comparative efficacy of Shatavari Ghrita eye drops with Shatavari Ksheerapaka versus Triphala Ghrita eye drops with Shatavari Ksheerapaka in postmenopausal ocular surface disease: a randomized, single-blind trial.Frontiers in medicine · 2026Trial
- Current and Developing Therapeutics for Dry Eye Disease: Targeting Ion Channels.Current issues in molecular biology · 2026Review
- Molecular landscape connecting complications of dry eye disease: mechanisms, therapeutic targets, biomarkers, and future innovations.International ophthalmology · 2026Review
- Immuno-inflammatory axis of menopausal dry eye: from hormonal fluctuations to ocular surface dysregulation.Frontiers in immunology · 2026Review
- Focus on sex hormone axis disorder: exploring the susceptibility mechanism of dry eye in perimenopausal women.Frontiers in medicine · 2026Review
- Menopause symptom awareness research across the globe: a scoping review.Frontiers in global women's health · 2026Review
- Dry Eye in Post-menopausal Women Visiting Community Eye Centre: An Observational Study.JNMA; journal of the Nepal Medical Association · 2025Observational
- Sex Differences in the Lacrimal Gland: Implications for Dry Eye Disease.International journal of molecular sciences · 2025Review
- Dry Eye Syndrome in Children during the COVID-19 Pandemic.Korean journal of ophthalmology : KJO · 2024Article
- Article
- Predicting Risks of Dry Eye Disease Development Using a Genome-Wide Polygenic Risk Score Model.Translational vision science & technology · 2024Article
- Review
- Retinal biomarkers for the risk of Alzheimer's disease and frontotemporal dementia.Frontiers in aging neuroscience · 2024Article
- Inflammation mechanism and anti-inflammatory therapy of dry eye.Frontiers in medicine · 2024Review
- Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.Annals of medicine · 2023Review
- The effects of female sex hormones on the human cornea across a woman's life cycle.BMC ophthalmology · 2023Review
- Analysis of risk factors for dry eye disease and effect of diquafosol sodium ophthalmic solution on the tear film after vitrectomy in patients with type 2 diabetes mellitus: a preliminary study.International ophthalmology · 2023Article
- Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials.Ophthalmology and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a multifactorial ocular surface disease that causes symptoms of ocular pain, discomfort, and decreased visual acuity. It significantly affects quality of life of patients. It is more prevalent in the females and is being specifically in the menopausal and postmenopausal age group. This is believed to be due to the changes in balance of sex hormones. Sex hormones - estrogens and androgens - influence production of all components of the tear film including aqueous layer, lipid, and mucin. Various mechanisms such as decrease in hormonal levels, shift in feedback mechanisms, and changes in receptor receptivity interplay to alter the ocular surface homeostasis and subsequently result in DED. Several studies have suggested potential role of hormone replacement therapy in menopause-associated dry eye symptoms. The purpose of this review is to help the non ophthalmic physicians about DED encountered commonly in menopausal age group. It is important for primary care physicians to understand DED due to its high prevalence, often debilitating symptoms and the potentially preventable and treatable nature of the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.